IPSEN (OTCMKTS:IPSEY) Stock Short Interest Report for October

IPSEN (OTCMKTS:IPSEY) was the target of a large decrease in short interest in October. As of October 15th, there was short interest totaling 606 shares, a decrease of 57.5% from the September 30th total of 1,426 shares. Approximately 0.0% of the shares of the company are short sold. Based on an average trading volume of 5,390 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

IPSEY has been the subject of several research reports. Jefferies Financial Group lowered shares of IPSEN from a “hold” rating to a “moderate sell” rating in a report on Sunday, August 2nd. Barclays raised shares of IPSEN from a “strong sell” rating to a “hold” rating in a report on Thursday, September 17th. Two equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have issued a Sell rating to the stock. According to data from MarketBeat.com, IPSEN has an average rating of “Hold”.

IPSEN Price Performance

OTCMKTS:IPSEY opened at $44.46 on Friday. IPSEN has a 12 month low of $34.34 and a 12 month high of $51.10. The company’s 50 day moving average is $43.96 and its 200-day moving average is $45.20.

IPSEN Company Profile

Ipsen SA is a France-based biopharmaceutical company focused on developing and commercializing medicines for serious diseases. Its principal therapeutic areas are oncology, rare diseases and neuroscience, with operations spanning research, clinical development, manufacturing and commercial activities.

The company’s portfolio includes medicines such as Somatuline (lanreotide) for certain neuroendocrine tumors and rare endocrine conditions, Dysport (abobotulinumtoxinA) for therapeutic and aesthetic uses, and Onivyde (a liposomal formulation of irinotecan) for pancreatic cancer.